Bridgewater Bancshares has just reported Q2 results, and the post-print picture looks meaningfully different from the defensive crouch options traders held heading into the release.
The options signal that dominated the pre-earnings note has not yet unwound. The put/call ratio remains at 12.1 — nearly three standard deviations above its 20-day average of 6.1 — and has held at that elevated level across both July 20 and July 21. Whether that reflects hedges still open, or fresh defensiveness in response to the actual numbers, is the key question. The ratio is still close to its 52-week peak of 15.7, making this among the most skewed options setups BWB has carried all year. The stock itself closed at $21.89, up 1.6% on the week and 11% over the past month, but gave back a fraction on the day of the print — a modest dip after a strong run.
Short interest is genuinely low, and the borrow market confirms that shorts are not a meaningful force here. SI amounts to 1.5% of the free float — barely worth tracking for squeeze dynamics. The cost to borrow has risen about 28% on the week to 0.65%, and is up roughly a third over the past month, but in absolute terms that remains near the floor. Availability is effectively unlimited, with over 12 million shares available to lend against fewer than 410,000 short. The ORTEX short score is running at 31.9, drifting just below where it was two weeks ago. Positioning looks loose rather than loaded — bears are not crowding this name.
The Street's read is constructively positioned but not aggressive. DA Davidson and Piper Sandler both held Buy and Overweight ratings respectively in January, with targets in the $23–$24 range, though neither has moved in the three months since. The mean analyst price target of $23.13 sits about 6% above the current price — a modest implied upside. The bull case rests on raised full-year loan growth guidance, upgraded to high single digits from mid-to-high single digits, strong core deposit expansion, and a track record of credit outperformance. The bear case centres on elevated operating expenses, potential NIM pressure, and the concentrated commercial real estate book. On valuation, the stock trades at roughly 10.8x trailing earnings and 1.14x book — neither stretched nor cheap for a Midwest commercial lender. The EPS surprise factor score ranks in the 95th percentile, meaning BWB has consistently beaten estimates, which anchors the bull case more firmly than the valuation alone would.
Among close peers, the regional bank tape has been broadly positive this week. MBWM gained 4.6% and FBIZ added 4.5%, both outpacing BWB's 1.6% weekly move. FRME and QCRH were mildly lower on the day. BWB's relative underperformance against that peer group on the week is a data point worth noting given that loan growth guidance was raised — either the print carried some offset, or the move into earnings had already done the work.
The insider register adds a layer of caution. The 90-day net activity shows roughly $1.2 million in net selling across multiple names, including the founder and director Jeffrey Shellberg, the CFO, and the COO — all selling in May and early June at prices in the $18.50–$19.30 range, well below the current $21.89. That selling predates the recent rally, so the significance is limited, but the absence of buying at those levels by anyone other than a token director purchase is worth filing away. The next earnings event is scheduled for October 21, which sets the calendar for when the next formal data checkpoint arrives.
What to watch now is whether the elevated put/call ratio begins to normalise following the print, and whether analysts who last moved in January update their targets to reflect the raised guidance.
See the live data behind this article on ORTEX.
Open BWB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
